Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4401 - 4425 of 8179 in total
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Investigational
Matched Description: … Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
Matched Description: … DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome. …
AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs. Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and...
Investigational
Matched Description: … approximately half of currently marketed drugs. ... anxiety, cancer, and a number of other serious conditions. ... metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … of fluid in the eye, is believed to be one of the principal causes of glaucoma. ... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount ... PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of
Marbofloxacin is a carboxylic acid, part of the third generation of antibiotic fluoroquinolones. It is used in veterinary medicine. A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon.
Vet approved
Matched Description: … Marbofloxacin is a carboxylic acid, part of the third generation of antibiotic fluoroquinolones. ... A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name …
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce ... [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 …
Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.
Investigational
Matched Description: … , and Safety of Amenamevir. ... Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis …
Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).
Investigational
Matched Description: … Therapy for Patients of IgA Nephropathy). ... Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside …
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … of a Deceased Donor Kidney). ... Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients …
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
Caricotamide is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).
Investigational
Matched Description: … of Prolarix™ in Hepatocellular Carcinoma). ... Caricotamide is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety …
Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment...
Investigational
Withdrawn
Matched Description: … treatment of pediatric leukemia. ... Clinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate ... Off label, aminopterin has also been used in the treatment of psoriasis. …
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... , and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. ... Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute …
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to ... the treatment of various solid tumors. ... DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
Investigational
Matched Description: … Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different …
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … a number of tumor cell types. ... It has been investigated for the treatment of hodgkin’s lymphoma. ... a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of
An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)
Experimental
Matched Description: … An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other ... It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6- …
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. ... Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide …
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of
GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).
Investigational
Matched Description: … Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients ... With Painful Osteoarthritis of the Knee). ... GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the …
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Matched Description: … MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 ... SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. ... convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Investigational
Matched Description: … Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml ... Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial …
Displaying drugs 4401 - 4425 of 8179 in total